At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Biosample collection (other)
- How long the study runs
- Study runs about 52 months (dates as stated)
- About the drug or intervention
- Biosample collection — other: Collection of saliva, urine, blood, breath and quality of life questionnaires.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years to 90 Years
- Who
- All
- Number of participants
- 100
- Started
- 2025-02
- Last checked
- 2025-02
Plain English Summary
What is this study?
- • Testing a new treatment for oesophageal adenocarcinoma
- • Clinical study - 100 participants
- • Oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in England and Wales with 16,000 new cases diagnosed every year
Who can take part?
- • Ages 18 Years to 90 Years
- • Diagnosed with oesophageal adenocarcinoma
Where?
- • London - Imperial College Healthcare NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in England and Wales with 16,000 new cases diagnosed every year. Survival rates are poor with only 15% surviving beyond 5 years. There is also increasing research to understand the cancer biology and factors allowing cancers to progress. It is likely there is a relationship between the cancer-specific microbiome, cells related to inflammation, which promotes cancer progression. The BIORESOURCE 1 study has established a comprehensive resource of matched samples from patients with oesophageal and gastric cancer. This longitudinal study aims to obtain further matched biosamples in the follow-up period after cancer surgery to find biomarkers that may predict treatment response, recurrence and/or long term prognosis.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 90 Years
- Who can join: All genders
What the study is looking for
- ✓Aged 18-90 years at the time of initial recruitment
- ✓Gastric/oesophageal adenocarcinoma cohort (biopsy proven adenocarcinoma) recruited into BIORESOURCE 1
Who cannot take part
- ✗Oesophageal squamous cell carcinoma
- ✗Previous oesophageal and gastric resection
- ✗History of another cancer within five years. If a new other cancer type is diagnosed within the sampling time frame,...
- ✗Participants with co-morbidities preventing breath collection
- ✗Unable or unwilling to provide informed written consent
See the full criteria
Where Is This Study? (1 UK site)
Imperial College Healthcare NHS Trust
London, United Kingdom
How to Get in Touch
Bhamini Vadhwana, MRCS, PhD
Sponsor contactCONTACT